Overall Survival (OS) - Percentage of Participants With an Event Baseline (BL), Days 1, 8, 15, 22, 43, 64, 85, 106, 127, and every 21 days until the end of study, 1 year after the cut-off date for the 2nd interim efficacy analysis [clinicaltrials_resource:447f4fcb069e7eaf25257f8a7af2dff4]
OS was defined as the time from the date of randomization to the date of death due to any cause. Participants were censored at the last date of tumor measurement, the last date in the study drug log, or the date of last follow-up.
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
Overall Survival (OS) - Percentage of Participants With an Event Baseline (BL), Days 1, 8, 15, 22, 43, 64, 85, 106, 127, and every 21 days until the end of study, 1 year after the cut-off date for the 2nd interim efficacy analysis [clinicaltrials_resource:447f4fcb069e7eaf25257f8a7af2dff4]
OS was defined as the time from the date of randomization to the date of death due to any cause. Participants were censored at the last date of tumor measurement, the last date in the study drug log, or the date of last follow-up.
Bio2RDF identifier
447f4fcb069e7eaf25257f8a7af2dff4
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:447f4fcb069e7eaf25257f8a7af2dff4
measure [clinicaltrials_vocabulary:measure]
Overall Survival (OS) - Percentage of Participants With an Event
time frame [clinicaltrials_vocabulary:time-frame]
Baseline (BL), Days 1, 8, 15, ...... 2nd interim efficacy analysis
description
OS was defined as the time fro ...... or the date of last follow-up.
identifier
clinicaltrials_resource:447f4fcb069e7eaf25257f8a7af2dff4
title
Overall Survival (OS) - Percen ...... 2nd interim efficacy analysis
@en
type
label
Overall Survival (OS) - Percen ...... f4fcb069e7eaf25257f8a7af2dff4]
@en